{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:29:10Z","timestamp":1761895750187},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,10,21]],"date-time":"2013-10-21T00:00:00Z","timestamp":1382313600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1186\/1471-2490-13-51","type":"journal-article","created":{"date-parts":[[2013,10,21]],"date-time":"2013-10-21T11:01:44Z","timestamp":1382353304000},"source":"Crossref","is-referenced-by-count":8,"title":["Health economics perspective of fesoterodine, tolterodine or solifenacin as first-time therapy for overactive bladder syndrome in the primary care setting in Spain"],"prefix":"10.1186","volume":"13","author":[{"given":"Antoni","family":"Sicras-Mainar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Rejas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Navarro-Artieda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alba","family":"Aguado-Jodar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amador","family":"Ruiz-Torrej\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Ib\u00e1\u00f1ez-Nolla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Kvasz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,10,21]]},"reference":[{"key":"412_CR1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/nau.20798","volume":"29","author":"BT Haylen","year":"2010","unstructured":"Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, Monga A, Petri E, Rizk DE, Sand PK, Schaer GN: An International Urogynecological Association (IUGA)\/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010, 29: 4-20.","journal-title":"Neurourol Urodyn"},{"key":"412_CR2","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1111\/j.1742-1241.2006.01127.x","volume":"60","author":"M Kirby","year":"2006","unstructured":"Kirby M, Artibani W, Cardozo L, Chapple C, Diaz DC, De Ridder D, Espuna-Pons M, Haab F, Kelleher C, Milsom I, Van Kerrebroeck P, Vierhout M, Wagg A: Overactive bladder: the importance of new guidance. Int J Clin Pract. 2006, 60: 1263-1271. 10.1111\/j.1742-1241.2006.01127.x.","journal-title":"Int J Clin Pract"},{"key":"412_CR3","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1517\/14656566.2011.554396","volume":"12","author":"JM Latini","year":"2011","unstructured":"Latini JM, Giannantoni A: Pharmacotherapy of overactive bladder: epidemiology and pathophysiology of overactive bladder. Expert Opin Pharmacother. 2011, 12: 1017-1027. 10.1517\/14656566.2011.554396.","journal-title":"Expert Opin Pharmacother"},{"key":"412_CR4","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.eururo.2006.09.019","volume":"50","author":"DE Irwin","year":"2006","unstructured":"Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, Coyne K, Kelleher C, Hampel C, Artibani W, Abrams P: Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006, 50: 1306-1315. 10.1016\/j.eururo.2006.09.019.","journal-title":"Eur Urol"},{"key":"412_CR5","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1046\/j.1464-410x.2001.02228.x","volume":"87","author":"I Milsom","year":"2001","unstructured":"Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ: How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001, 87: 760-766.","journal-title":"BJU Int"},{"key":"412_CR6","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","volume":"20","author":"WF Stewart","year":"2003","unstructured":"Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, Hunt TL, Wein AJ: Prevalence and burden of overactive bladder in the United States. World J Urol. 2003, 20: 327-336.","journal-title":"World J Urol"},{"key":"412_CR7","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1111\/j.1742-1241.2006.01057.x","volume":"60","author":"IA Odeyemi","year":"2006","unstructured":"Odeyemi IA, Dakin HA, O\u2019Donnell RA, Warner J, Jacobs A, Dasgupta P: Epidemiology, prescribing patterns and resource use associated with overactive bladder in UK primary care. Int J Clin Pract. 2006, 60: 949-958. 10.1111\/j.1742-1241.2006.01057.x.","journal-title":"Int J Clin Pract"},{"key":"412_CR8","doi-asserted-by":"publisher","first-page":"e195","DOI":"10.1371\/journal.pone.0000195","volume":"2","author":"KA Tikkinen","year":"2007","unstructured":"Tikkinen KA, Tammela TL, Rissanen AM, Valpas A, Huhtala H, Auvinen A: Is the prevalence of overactive bladder overestimated? A population-based study in Finland. PLoS ONE. 2007, 2: e195-10.1371\/journal.pone.0000195.","journal-title":"PLoS ONE"},{"key":"412_CR9","doi-asserted-by":"publisher","first-page":"131","DOI":"10.4321\/S0004-06142005000200006","volume":"58","author":"D Castro","year":"2005","unstructured":"Castro D, Espuna M, Prieto M, Badia X: Prevalence of overactive bladder in Spain: a population-based study. Arch Esp Urol. 2005, 58: 131-138.","journal-title":"Arch Esp Urol"},{"key":"412_CR10","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0210-4806(09)74117-8","volume":"33","author":"E Martinez Agullo","year":"2009","unstructured":"Martinez Agullo E, Ruiz Cerda JL, Gomez Perez L, Ram\u00edrez Backhaus M, Delgado Oliva F, Rebollo P, Gonz\u00e1lez-Segura Alsina D, Arumi D: Prevalence of urinary incontinence and hyperactive bladder in the Spanish population: results of the EPICC study. Actas Urol Esp. 2009, 33: 159-166. 10.1016\/S0210-4806(09)74117-8.","journal-title":"Actas Urol Esp"},{"key":"412_CR11","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1111\/j.1532-5415.2011.03492.x","volume":"59","author":"CC Sexton","year":"2011","unstructured":"Sexton CC, Coyne KS, Thompson C, Bavendam T, Chen CI, Markland A: Prevalence and effect on health-related quality of life of overactive bladder in older americans: results from the epidemiology of lower urinary tract symptoms study. J Am Geriatr Soc. 2011, 59: 1465-1470. 10.1111\/j.1532-5415.2011.03492.x.","journal-title":"J Am Geriatr Soc"},{"key":"412_CR12","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.eururo.2011.01.031","volume":"59","author":"CP Vaughan","year":"2011","unstructured":"Vaughan CP, Johnson TM, Ala-Lipasti MA, Cartwright R, Tammela TL, Taari K, Auvinen A, Tikkinen KA: The prevalence of clinically meaningful overactive bladder: bother and quality of life results from the population-based FINNO study. Eur Urol. 2011, 59: 629-636. 10.1016\/j.eururo.2011.01.031.","journal-title":"Eur Urol"},{"key":"412_CR13","doi-asserted-by":"publisher","first-page":"143","DOI":"10.5213\/inj.2011.15.3.143","volume":"15","author":"ES Yoo","year":"2011","unstructured":"Yoo ES, Kim BS, Kim DY, Oh SJ, Kim JC: The impact of overactive bladder on health-related quality of life, sexual life and psychological health in Korea. Int Neurourol J. 2011, 15: 143-151. 10.5213\/inj.2011.15.3.143.","journal-title":"Int Neurourol J"},{"key":"412_CR14","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.acuro.2009.09.001","volume":"34","author":"E Martinez Agullo","year":"2010","unstructured":"Martinez Agullo E, Ruiz Cerda JL, Gomez Perez L, Rebollo P, Perez M, Chaves J: Impact of urinary incontinence and overactive bladder syndrome on health-related quality of life of working middle-aged patients and institutionalized elderly patients. Actas Urol Esp. 2010, 34: 242-250.","journal-title":"Actas Urol Esp"},{"key":"412_CR15","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.urology.2009.07.1325","volume":"75","author":"S Bartoli","year":"2010","unstructured":"Bartoli S, Aguzzi G, Tarricone R: Impact on quality of life of urinary incontinence and overactive bladder: a systematic literature review. Urology. 2010, 75: 491-500. 10.1016\/j.urology.2009.07.1325.","journal-title":"Urology"},{"key":"412_CR16","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.eururo.2008.01.027","volume":"53","author":"DE Irwin","year":"2008","unstructured":"Irwin DE, Milsom I, Kopp Z, Abrams P: Symptom bother and health care-seeking behavior among individuals with overactive bladder. Eur Urol. 2008, 53: 1029-1037. 10.1016\/j.eururo.2008.01.027.","journal-title":"Eur Urol"},{"key":"412_CR17","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1016\/j.juro.2009.02.018","volume":"181","author":"JS Benner","year":"2009","unstructured":"Benner JS, Becker R, Fanning K, Jumadilova Z, Bavendam T, Brubaker L: Bother related to bladder control and health care seeking behavior in adults in the United States. J Urol. 2009, 181: 2591-2598. 10.1016\/j.juro.2009.02.018.","journal-title":"J Urol"},{"key":"412_CR18","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.eururo.2010.11.040","volume":"59","author":"KE Andersson","year":"2011","unstructured":"Andersson KE: Antimuscarinic mechanisms and the overactive detrusor: an update. Eur Urol. 2011, 59: 377-386. 10.1016\/j.eururo.2010.11.040.","journal-title":"Eur Urol"},{"key":"412_CR19","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1002\/nau.21051","volume":"30","author":"KF Hunter","year":"2011","unstructured":"Hunter KF, Wagg A, Kerridge T, Chick H, Chambers T: Falls risk reduction and treatment of overactive bladder symptoms with antimuscarinic agents: a scoping review. Neurourol Urodyn. 2011, 30: 490-494. 10.1002\/nau.21051.","journal-title":"Neurourol Urodyn"},{"key":"412_CR20","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/j.1464-410X.2010.09882.x","volume":"108","author":"P Swinburn","year":"2011","unstructured":"Swinburn P, Lloyd A, Ali S, Hashmi N, Newal D, Najib H: Preferences for antimuscarinic therapy for overactive bladder. BJU Int. 2011, 108: 868-873.","journal-title":"BJU Int"},{"key":"412_CR21","first-page":"807","volume":"68","author":"L Dobrek","year":"2011","unstructured":"Dobrek L, Juszczak K, Wyczolkowski M, Thor PJ: Current management and future perspectives of overactive bladder (OAB) pharmacotherapy. Acta Pol Pharm. 2011, 68: 807-821.","journal-title":"Acta Pol Pharm"},{"key":"412_CR22","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1111\/j.1464-410X.2008.07907.x","volume":"102","author":"C Chapple","year":"2008","unstructured":"Chapple C, Van Kerrebroeck P, Juenemann K, Wang J, Brodsky M: Comparison of fesoterodine and tolterodine in subjects with overactive bladder. BJU Int. 2008, 102: 1128-1132. 10.1111\/j.1464-410X.2008.07907.x.","journal-title":"BJU Int"},{"key":"412_CR23","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.eururo.2007.07.009","volume":"52","author":"C Chapple","year":"2007","unstructured":"Chapple C, Van Kerrebroeck P, Tubaro A, Haag-Molkenteller C, Forst HT, Massow U, Wang J, Brodsky M: Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol. 2007, 52: 1204-1212. 10.1016\/j.eururo.2007.07.009.","journal-title":"Eur Urol"},{"key":"412_CR24","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1185\/03007995.2011.565044","volume":"27","author":"J Corcos","year":"2011","unstructured":"Corcos J, Angulo JC, Garely AD, Carlsson M, Gong J, Guan Z: Effect of fesoterodine 4 mg on bladder diary and patient-reported outcomes during the first week of treatment in subjects with overactive bladder. Curr Med Res Opin. 2011, 27: 1059-1065. 10.1185\/03007995.2011.565044.","journal-title":"Curr Med Res Opin"},{"key":"412_CR25","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/j.1464-410X.2009.09086.x","volume":"105","author":"S Herschorn","year":"2010","unstructured":"Herschorn S, Swift S, Guan Z, Carlsson M, Morrow JD, Brodsky M, Gong J: Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. BJU Int. 2010, 105: 58-66. 10.1111\/j.1464-410X.2009.09086.x.","journal-title":"BJU Int"},{"key":"412_CR26","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1016\/j.juro.2007.08.033","volume":"178","author":"VW Nitti","year":"2007","unstructured":"Nitti VW, Dmochowski R, Sand PK, Forst HT, Haag-Molkenteller C, Massow U, Wang J, Brodsky M, Bavendam T: Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. J Urol. 2007, 178: 2488-2494. 10.1016\/j.juro.2007.08.033.","journal-title":"J Urol"},{"key":"412_CR27","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/j.1464-410X.2008.07710.x","volume":"102","author":"CJ Kelleher","year":"2008","unstructured":"Kelleher CJ, Tubaro A, Wang JT, Kopp Z: Impact of fesoterodine on quality of life: pooled data from two randomized trials. BJU Int. 2008, 102: 56-61. 10.1111\/j.1464-410X.2008.07710.x.","journal-title":"BJU Int"},{"key":"412_CR28","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1111\/j.1742-1241.2010.02626.x","volume":"65","author":"CC Sexton","year":"2011","unstructured":"Sexton CC, Notte SM, Maroulis C, Dmochowski RR, Cardozo L, Subramanian D, Coyne KS: Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature. Int J Clin Pract. 2011, 65: 567-585. 10.1111\/j.1742-1241.2010.02626.x.","journal-title":"Int J Clin Pract"},{"key":"412_CR29","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1111\/j.1464-410X.2009.09036.x","volume":"105","author":"JS Benner","year":"2010","unstructured":"Benner JS, Nichol MB, Rovner ES, Jumadilova Z, Alvir J, Hussein M, Fanning K, Trocio JN, Brubaker L: Patient-reported reasons for discontinuing overactive bladder medication. BJU Int. 2010, 105: 1276-1282. 10.1111\/j.1464-410X.2009.09036.x.","journal-title":"BJU Int"},{"key":"412_CR30","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.urology.2010.01.080","volume":"76","author":"JH Watanabe","year":"2010","unstructured":"Watanabe JH, Campbell JD, Ravelo A, Chancellor MB, Kowalski J, Sullivan SD: Cost analysis of interventions for antimuscarinic refractory patients with overactive bladder. Urology. 2010, 76: 835-840. 10.1016\/j.urology.2010.01.080.","journal-title":"Urology"},{"key":"412_CR31","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.eururo.2006.04.018","volume":"50","author":"P Reeves","year":"2006","unstructured":"Reeves P, Irwin D, Kelleher C, Milsom I, Kopp Z, Calvert N, Lloyd A: The current and future burden and cost of overactive bladder in five European countries. Eur Urol. 2006, 50: 1050-1057. 10.1016\/j.eururo.2006.04.018.","journal-title":"Eur Urol"},{"issue":"4 Suppl","key":"412_CR32","first-page":"S101","volume":"11","author":"CD Mullins","year":"2005","unstructured":"Mullins CD, Subak LL: New perspectives on overactive bladder: quality of life impact, medication persistency, and treatment costs. Am J Manag Care. 2005, 11 (4 Suppl): S101-S102.","journal-title":"Am J Manag Care"},{"key":"412_CR33","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology: Anatomic Therapeutic Chemical classification system: structure and principles. Available at: http:\/\/www.whocc.no\/atc\/structure_and_principles\/#structure . Accessed: March 13, 2013,"},{"key":"412_CR34","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0895-4356(96)00268-5","volume":"50","author":"JF Steiner","year":"1997","unstructured":"Steiner JF, Prochazka AV: The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997, 50: 105-116. 10.1016\/S0895-4356(96)00268-5.","journal-title":"J Clin Epidemiol"},{"key":"412_CR35","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1001\/jama.288.4.455","volume":"288","author":"JS Benner","year":"2002","unstructured":"Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J: Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002, 288: 455-461. 10.1001\/jama.288.4.455.","journal-title":"JAMA"},{"key":"412_CR36","volume-title":"With a Multi-language Layer","author":"The International Classification of Primary Care in the European Community","year":"1993","unstructured":"The International Classification of Primary Care in the European Community: With a Multi-language Layer. 1993, Oxford: Oxford Medical Publications"},{"key":"412_CR37","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987, 40: 373-383. 10.1016\/0021-9681(87)90171-8.","journal-title":"J Chronic Dis"},{"key":"412_CR38","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1136\/bmj.320.7243.1197","volume":"320","author":"SG Thompson","year":"2000","unstructured":"Thompson SG, Barber JA: How should cost data in pragmatic randomised trials be analysed?. BMJ. 2000, 320: 1197-1200. 10.1136\/bmj.320.7243.1197.","journal-title":"BMJ"},{"key":"412_CR39","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1111\/j.1464-410X.2010.09640.x","volume":"107","author":"SA Kaplan","year":"2011","unstructured":"Kaplan SA, Schneider T, Foote JE, Guan Z, Carlsson M, Gong J: Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. BJU Int. 2011, 107: 1432-1440. 10.1111\/j.1464-410X.2010.09640.x.","journal-title":"BJU Int"},{"key":"412_CR40","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1471-2490-12-19","volume":"12","author":"D Castro-Diaz","year":"2012","unstructured":"Castro-Diaz D, Miranda P, Sanchez-Ballester F, Lizarraga I, Arumi D, Rejas J: Dose and aging effect on patients reported treatment benefit switching from the first overactive bladder therapy with tolterodine Er to fesoterodine: post-hoc analysis from an observational and retrospective study. BMC Urol. 2012, 12: 19-10.1186\/1471-2490-12-19.","journal-title":"BMC Urol"},{"key":"412_CR41","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1097\/01.ju.0000140729.07840.16","volume":"172","author":"L Cardozo","year":"2004","unstructured":"Cardozo L, Lisec M, Millard R, van Vierssen TO, Kuzmin I, Drogendijk TE, Huang M, Ridder AM: Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol. 2004, 172: 1919-1924. 10.1097\/01.ju.0000140729.07840.16.","journal-title":"J Urol"},{"key":"412_CR42","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1464-410X.2004.04606.x","volume":"93","author":"CR Chapple","year":"2004","unstructured":"Chapple CR, Rechberger T, Al-Shukri S, Meffan P, Everaert K, Huang M, Ridder A: Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int. 2004, 93: 303-310. 10.1111\/j.1464-410X.2004.04606.x.","journal-title":"BJU Int"},{"key":"412_CR43","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.eururo.2005.05.015","volume":"48","author":"CR Chapple","year":"2005","unstructured":"Chapple CR, Martinez-Garcia R, Selvaggi L, Toozs-Hobson P, Warnack W, Drogendijk T, Wright DM, Bolodeoku J: A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol. 2005, 48: 464-470. 10.1016\/j.eururo.2005.05.015.","journal-title":"Eur Urol"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2490-13-51\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2490-13-51.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2490-13-51","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2490-13-51.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T20:15:44Z","timestamp":1716063344000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/1471-2490-13-51"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,21]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["412"],"URL":"https:\/\/doi.org\/10.1186\/1471-2490-13-51","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,21]]},"article-number":"51"}}